TCRT Insider Trading

Insider Ownership Percentage: 5.11%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Alaunos Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Alaunos Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

Alaunos Therapeutics Share Price & Price History

Current Price: $1.78
Price Change: Price Increase of +0.05 (2.89%)
As of 01/17/2025 04:58 PM ET

This chart shows the closing price history over time for TCRT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
FebMarAprMayJunJulAugSepOctNovDecJan$1.78Closing price on 01/20/25:

Alaunos Therapeutics Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Alaunos Therapeutics (NASDAQ:TCRT)

27.72% of Alaunos Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TCRT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$0bought$1.62MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$20M$0$20MTotal InflowsTotal Outflows
Alaunos Therapeutics logo
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
Read More on Alaunos Therapeutics

Today's Range

Now: $1.78
Low: $1.70
High: $1.80

50 Day Range

MA: $2.09
Low: $1.64
High: $2.81

52 Week Range

Now: $1.78
Low: $1.63
High: $32.85

Volume

18,974 shs

Average Volume

24,775 shs

Market Capitalization

$2.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Alaunos Therapeutics?

Alaunos Therapeutics' top insider investors include:
  1. Kevin S Sr Boyle (CEO)
Learn More about top insider investors at Alaunos Therapeutics.